VIKING THERAPEUTICS INC

NASDAQ: VKTX (Viking Therapeutics, Inc.)

Last update: 24 Jun, 11:23PM

26.95

2.09 (8.41%)

  • 1D 8.41%
  • 5D -4.33%
  • 1M -0.04%
  • 6M -17.23%
  • YTD -34.46%
  • 1Y -52.72%
  • 5Y 279.58%
Previous Close 24.86
Open 25.30
Volume 4,356,088
Avg. Volume (3M) 3,808,385
Market Cap 3,026,754,560
Price / Book 3.74
52 Weeks Range
18.92 (-29%) — 81.73 (203%)
Earnings Date 22 Jul 2025 - 28 Jul 2025
Diluted EPS (TTM) -1.16
Total Debt/Equity (MRQ) 0.12%
Current Ratio (MRQ) 44.25
Operating Cash Flow (TTM) -133.99 M
Levered Free Cash Flow (TTM) -98.38 M
Return on Assets (TTM) -11.74%
Return on Equity (TTM) -14.40%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Bearish
Biotechnology (Global) Mixed Bearish
Stock Viking Therapeutics, Inc. Bullish Bearish

AIStockmoo Score

3.4
Analyst Consensus 5.0
Insider Activity 3.0
Price Volatility 4.5
Technical Moving Averages 2.5
Technical Oscillators 2.0
Average 3.40

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
VKTX 3 B - - 3.74
BPMC 8 B - - 24.41
CORT 8 B - 62.10 11.29
NUVL 6 B - - 6.01
RYTM 6 B - - 300.55
ADMA 4 B - 22.04 11.83

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Sector Healthcare
Industry Biotechnology
Investment Style Small Growth
% Held by Insiders 2.12%
% Held by Institutions 70.04%
52 Weeks Range
18.92 (-29%) — 81.73 (203%)
Price Target Range
75.00 (178%) — 104.00 (285%)
High 104.00 (Cantor Fitzgerald, 285.90%) Buy
Median 102.00 (278.48%)
Low 75.00 (Truist Securities, 178.29%) Buy
Average 95.75 (255.29%)
Total 4 Buy
Avg. Price @ Call 26.16
Firm Date Target Price Call Price @ Call
HC Wainwright & Co. 25 Jun 2025 102.00 (278.48%) Buy 27.09
24 Apr 2025 102.00 (278.48%) Buy 25.66
Cantor Fitzgerald 28 Apr 2025 104.00 (285.90%) Buy 25.94
Truist Securities 28 Apr 2025 75.00 (178.29%) Buy 25.94
Morgan Stanley 24 Apr 2025 102.00 (278.48%) Buy 25.66
Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
LIAN BRIAN 27.72 28.19 21,444 581,790
MANCINI MARIANNA 27.72 28.19 3,401 92,271
ZANTE GREG 27.72 28.19 3,401 92,271
Aggregate Net Quantity 28,246
Aggregate Net Value ($) 766,331
Aggregate Avg. Buy ($) 27.72
Aggregate Avg. Sell ($) 28.19
Insider Range ($)
27.72 (2%) — 28.19 (4%)
Name Holder Date Type Quantity Price Value ($)
MANCINI MARIANNA Officer 03 Jul 2025 Sell (-) 4,266 28.19 120,259
LIAN BRIAN Officer 03 Jul 2025 Sell (-) 26,889 28.19 758,001
ZANTE GREG Officer 03 Jul 2025 Sell (-) 4,266 28.19 120,259
MANCINI MARIANNA Officer 02 Jul 2025 Acquired (+) 7,667 27.72 212,529
LIAN BRIAN Officer 02 Jul 2025 Acquired (+) 48,333 27.72 1,339,791
ZANTE GREG Officer 02 Jul 2025 Acquired (+) 7,667 27.72 212,529

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria